42T Archives - BioTuesdays

Developments

Omeq Medical receives FDA approval for epidural injections smart device

Closely-held Omeq Medical, a portfolio company of Israel’s The Trendlines Group (SGX:42T;TCQX:TRNLY), received regulatory clearance from the FDA for its EpiFinder device, which assists physicians to accurately position...

May 9, 2023

Developments

SenterCare in pact to bring aging-at-home-safely technology to Japan

Closely-held SenterCare, a member of the Trendlines Group of Israel, and Nozomi MedAlliance established an alliance to bring SenterCare’s advanced aging-at-home-safely technology to the Japanese market. SenterCare has...

February 21, 2023

Developments

liberDi receives FDA clearance for digital home dialysis system

liberDi, a portfolio company of The Trendlines Group (OTCQX:TRNLY), received regulatory clearance from the FDA for its Digital Dialysis Clinic, which allows patients to perform dialysis at home or at the workplace, by...

January 4, 2023

Feature

Trendlines’ PregnanTech developing Lioness device to prevent preterm birth

Closely-held PregnanTech is completing a clinical safety study with its Lioness device to prevent preterm birth in non-pregnant women about to undergo a hysterectomy as a steppingstone to a larger proof-of-concept study...

September 22, 2020

Developments

Trendlines OrthoSpin receives FDA clearance for robotic orthopedic treatments

OrthoSpin, a portfolio of company of The Trendlines Group (OTCQX:TRNLY; SGX:42T) received regulatory clearance from the FDA for its smart, robotic external fixation system for orthopedic treatments. The use of external...

September 18, 2019

Feature

Vessi Medical developing new treatment for superficial bladder cancer

By Len Zehr Closely-held Vessi Medical wants to change the standard of care for superficial bladder cancer by using a surface cryotherapy approach in a minimally invasive in-office treatment alternative to surgery. “We...

March 26, 2019

Developments

Vessi Medical posts positive preclinical surface cryoablation results for bladder cancer

Closely-held Vessi Medical, a member of Israel’s Trendlines Group (OTCQX:TRNLY; SGX:42T), reported a successful animal study demonstrating the use of its surface cryoablation therapy inside the urinary bladder...

January 22, 2019

Feature

Trendlines cites hands-on approach to growth of its investment portfolio

With 11 years of progressive growth in the value of its expanding portfolio, The Trendlines Group (SGX:42T; OTCQX:TRNLY), an Israeli investment company, takes a very hands-on approach with its early-stage medical and...

November 6, 2018

Tag - 42T

Omeq Medical receives FDA approval for epidural injections smart device

SenterCare in pact to bring aging-at-home-safely technology to Japan

liberDi receives FDA clearance for digital home dialysis system

Trendlines’ PregnanTech developing Lioness device to prevent preterm birth

Trendlines OrthoSpin receives FDA clearance for robotic orthopedic treatments

Vessi Medical developing new treatment for superficial bladder cancer

Vessi Medical posts positive preclinical surface cryoablation results for bladder cancer

Trendlines cites hands-on approach to growth of its investment portfolio

General

More